Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study

American Heart Journal

Volumn 167, Issue 2, 2014, Pages

  Chin, Kelly M ^a   Badesch, David B ^b   Robbins, Ivan M ^c   Tapson, Victor F ^d   Palevsky, Harold I ^e   Kim, Nick H ^f   Kawut, Steven M ^e   Frost, Adaani ^g   Benton, Wade W ^h   Lemarie, Jean Christophe ⁱ   Bodin, Frederic ^j   Rubin, Lewis J ^f   McLaughlin, Vallerie ^k  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h Actelion Pharmaceuticals US Inc   (United States)

ⁱ Effi Stat   (France)

^j ACTELION PHARMACEUTICALS LTD   (Switzerland)

^k UNIVERSITY OF MICHIGAN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

6 KETO PROSTACYCLIN F1ALPHA; 6,15 DIKETO 13,14 DIHYDRO PROSTACYCLIN F1ALPHA; ANTIHYPERTENSIVE AGENT; DRUG METABOLITE; ENDOTHELIN RECEPTOR ANTAGONIST; NAFCILLIN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; TEZOSENTAN; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FAINTNESS; FEMALE; FLUSHING; FOLLOW UP; GENETIC DISORDER; HEART RATE; HEART RIGHT VENTRICLE FAILURE; HOSPITAL DISCHARGE; HUMAN; IDIOPATHIC DISEASE; INFECTION; JAW PAIN; KIDNEY FAILURE; LIMB PAIN; LIVER DISEASE; LIVER FUNCTION TEST; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PHASE 4 CLINICAL TRIAL; PHYSICAL CAPACITY; PHYSICIAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; VOMITING; WALKING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOPROSTENOL; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892781340     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.08.008     Document Type: Article

References (20)

1. L.J. Rubin, J. Mendoza, and M. Hood et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial Ann Intern Med 112 1990 485 491
2. R.J. Barst, L.J. Rubin, and W.A. Long et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension N Engl J Med 334 1996 296 301
3. D.B. Badesch, V.F. Tapson, and M.D. McGoon et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial Ann Intern Med 132 2000 425 434
4. R.J. Barst, J.S. Gibbs, and H.A. Ghofrani et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension J Am Coll Cardiol 54 2009 S78 S84
5. N. Galie, M.M. Hoeper, and M. Humbert et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537
6. O. Lambert, D. Bandilla, and R. Lyer et al. Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted Drug Des Dev Ther 6 2012 61 70
7. Veletri first and second generation prescribing information. http://www.veletri.com/hcp-prescribing-information.asp. Accessed December 31, 2013.
8. L.B. Nicolas, A. Krause, and M.M. Gutierrez et al. Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects Br J Clin Pharmacol 74 2012 978 989
9. O. Sitbon, M. Humbert, and H. Nunes et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 2002 780 788
10. R.J. Raymond, A.L. Hinderliter, and P.W. Willis et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension J Am Coll Cardiol 39 2002 1214 1219
11. M.M. Hoeper, H. Gall, and H.J. Seyfarth et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension Eur Respir J 34 2009 132 137
12. K.M. Chin, R.N. Channick, and N.H. Kim et al. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels Chest 132 2007 786 792
13. V.V. McLaughlin, A. Shillington, and S. Rich Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 2002 1477 1482
14. R.P. Frantz, M. Chakinala, and R.J. Barst et al. Bloodstream infection rates in patients with pulmonary arterial hypertension treated with epoprostenol for injection (Veletri®): a PROSPECT registry analysis Chest 142 2012 807A [Abstract]
15. N. Kitterman, A. Poms, and D.P. Miller et al. Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY(R) Mayo Clin Proc 87 2012 825 834
16. R.J. Oudiz, A. Widlitz, and X.J. Beckmann et al. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension Chest 126 2004 90 94
17. A.J. Kallen, E. Lederman, and A. Balaji et al. Bloodstream infections in patients given treatment with intravenous prostanoids Infect Control Hosp Epidemiol 29 2008 342 349
18. Centers for Disease Control and Prevention Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension - seven sites, United States, 2003-2006 MMWR Morb Mortal Wkly Rep 56 2007 170 172
19. D. Baum, A.C. Brown, and S.C. Church Effect of sedation on oxygen consumption of children undergoing cardiac catheterization Pediatrics 39 1967 891 895
20. K. Bauer, J. Ketteler, and M. Hellwig et al. Oral glucose before venepuncture relieves neonates of pain, but stress is still evidenced by increase in oxygen consumption, energy expenditure, and heart rate Pediatr Res 55 2004 695 700